促红细胞生成素，一个更新，在哪里，在未来?

EDTNA/ERCA journal (English ed.) Pub Date : 1998-07-01

S Sulková

{"title":"促红细胞生成素，一个更新，在哪里，在未来?","authors":"S Sulková","doi":"","DOIUrl":null,"url":null,"abstract":"Recombinant human erythropoietin has been produced by genetic technology since 1985 and since then many clinical trials have repeatedly demonstrated its success in the correction of anaemia associated with renal failure. This paper discusses basic principles for its administration, potential side effects and strategies for non response to erythropoietin (Epo) therapy.","PeriodicalId":79589,"journal":{"name":"EDTNA/ERCA journal (English ed.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1998-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Erythropoietin, an update, and where to in the future?\",\"authors\":\"S Sulková\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recombinant human erythropoietin has been produced by genetic technology since 1985 and since then many clinical trials have repeatedly demonstrated its success in the correction of anaemia associated with renal failure. This paper discusses basic principles for its administration, potential side effects and strategies for non response to erythropoietin (Epo) therapy.\",\"PeriodicalId\":79589,\"journal\":{\"name\":\"EDTNA/ERCA journal (English ed.)\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EDTNA/ERCA journal (English ed.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EDTNA/ERCA journal (English ed.)","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

重组人促红细胞生成素自1985年以来一直通过基因技术生产，自那时以来，许多临床试验一再证明其在纠正肾功能衰竭相关贫血方面取得了成功。本文讨论了其给药的基本原理，潜在的副作用和对促红细胞生成素(Epo)治疗无反应的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Erythropoietin, an update, and where to in the future?

Recombinant human erythropoietin has been produced by genetic technology since 1985 and since then many clinical trials have repeatedly demonstrated its success in the correction of anaemia associated with renal failure. This paper discusses basic principles for its administration, potential side effects and strategies for non response to erythropoietin (Epo) therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

EDTNA/ERCA journal (English ed.)

自引率

0.00%

发文量